Poster: CLL-045 The Dedalo Protocol: An Integrated Approach to MRD in CLL Patients Receiving Venetoclax Plus Rituximab
Clinical Lymphoma Myeloma and Leukemia(2022)
摘要
With all patients still on treatment, favorable MRD kinetics was observed in the venetoclax-rituximab setting. The majority of patients achieved PB uMRD after the first cycle of the treatment, with a higher percentage after the sixth cycle. These results are superimposable to those from MURANO trial (at 4 months, uMRD 60%, low MRD positivity 20%, 78% at 6 months). The durability of uMRD rates, their role in the prediction of PFS in a real-life experience, and the effect of genetic characteristics on the MRD kinetics are still under investigation.
更多查看译文
关键词
CLL,chronic lymphocytic leukemia,MURANO,MRD,venetoclax,rituximab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要